The DOI matches its Crossref record; 79 of the 79 references it cites were found in a registry or an index.
4. Comprehensive Medical Evaluation and Assessment of Comorbidities:Standards of Care in Diabetes—2023
Open accessAbstract
The American Diabetes Association (ADA) “Standards of Care in Diabetes” includes the ADA’s current clinical practice recommendations and is intended to provide the components of diabetes care, general treatment goals and guidelines, and tools to evaluate quality of care. Members of the ADA Professional Practice Committee, a multidisciplinary expert committee, are responsible for updating the Standards of Care annually, or more frequently as warranted. For a detailed description of ADA standards, statements, and reports, as well as the evidence-grading system for ADA’s clinical practice recommendations and a full list of Professional Practice Committee members, please refer to Introduction and Methodology. Readers who wish to comment on the Standards of Care are invited to do so at professional.diabetes.org/SOC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nalbandian, A., Sehgal, K., Gupta, A., Madhavan, M. V., McGroder, C., Stevens, J. S., Cook, J. R., Nordvig, A. S., Shalev, D., Sehrawat, T. S., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01283-z · Cited by 4,862
EASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease
(2016) · Journal of Hepatology · doi:10.1016/j.jhep.2015.11.004 · Cited by 4,836
Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis
Sanyal, A. J., Chalasani, N., Kowdley, K. V., McCullough, A., Diehl, A. M., Bass, N. M., Neuschwander-Tetri, B. A., Lavine, J. E., Tonascia, J., Unalp, A., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0907929 · Cited by 3,327
Rinella, M. E., Neuschwander-Tetri, B. A., Siddiqui, M. S., Abdelmalek, M. F., Caldwell, S., Barb, D., Kleiner, D. E., & Loomba, R. (2023) · Hepatology · doi:10.1097/hep.0000000000000323 · Cited by 2,667
Ekstedt, M., Hagström, H., Nasr, P., Fredrikson, M., Stål, P., Kechagias, S., & Hultcrantz, R. (2015) · Hepatology · doi:10.1002/hep.27368 · Cited by 2,287
Younossi, Z. M., Golabi, P., de Avila, L., Paik, J. M., Srishord, M., Fukui, N., Qiu, Y., Burns, L., Afendy, A., & Nader, F. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2019.06.021 · Cited by 2,235
Self-citationRisk of dementia in diabetes mellitus: a systematic review
Biessels, G. J., Staekenborg, S., Brunner, E., Brayne, C., & Scheltens, P. (2006) · The Lancet Neurology · doi:10.1016/s1474-4422(05)70284-2 · Cited by 2,187
Davies, M. J., Aroda, V. R., Collins, B. S., Gabbay, R. A., Green, J., Maruthur, N. M., Rosas, S. E., Del Prato, S., Mathieu, C., Mingrone, G., et al. (2022) · Diabetes Care · doi:10.2337/dci22-0034 · Cited by 2,104
Self-citationA Placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis
Newsome, P. N., Buchholtz, K., Cusi, K., Linder, M., Okanoue, T., Ratziu, V., Sanyal, A. J., Sejling, A.-S., & Harrison, S. A. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2028395 · Cited by 2,039
Self-citationMechanisms and disease consequences of nonalcoholic fatty liver disease
Loomba, R., Friedman, S. L., & Shulman, G. I. (2021) · Cell · doi:10.1016/j.cell.2021.04.015 · Cited by 2,002
Research works printed but not linked: 166
- Stellefson, 2013, The chronic care model and diabetes management in US primary care settings: a systematic review, Prev Chronic Dis, 10, E26, 10.5888/pcd10.120180 · DOI · Paper page
- Gabbay, 2011, Multipayer patient-centered medical home implementation guided by the chronic care model, Jt Comm J Qual Patient Saf, 37, 265
- UK Prospective Diabetes Study (UKPDS) Group, 1998, Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33), Lancet, 352, 837, 10.1016/S0140-6736(98)07019-6 · DOI · Paper page
- Diabetes Control and Complications Trial Research Group; NathanDM, GenuthS, LachinJ, The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med1993;329:977–986 · DOI · Paper page
- White, 2001, Beneficial effects of intensive therapy of diabetes during adolescence: outcomes after the conclusion of the Diabetes Control and Complications Trial (DCCT), J Pediatr, 139, 804, 10.1067/mpd.2001.118887 · DOI · Paper page
- Rodriguez, 2022, Improving quality outcomes: the value of diabetes care and education specialists, Clin Diabetes, 40, 356, 10.2337/cd21-0089 · DOI
- Anderson, 2000, Compliance and adherence are dysfunctional concepts in diabetes care, Diabetes Educ, 26, 597, 10.1177/014572170002600405 · DOI · Paper page
- Sarkar, 2006, Is self-efficacy associated with diabetes self-management across race/ethnicity and health literacy?, Diabetes Care, 29, 823, 10.2337/diacare.29.04.06.dc05-1615 · DOI · Paper page
- Lee, 2017, The impact of sleep amount and sleep quality on glycemic control in type 2 diabetes: a systematic review and meta-analysis, Sleep Med Rev, 31, 91, 10.1016/j.smrv.2016.02.001 · DOI · Paper page
- Robinson, 2020, Advisory Committee on Immunization Practices recommended immunization schedule for children and adolescents aged 18 years or younger—United States, 2020, MMWR Morb Mortal Wkly Rep, 69, 130, 10.15585/mmwr.mm6905a3 · DOI
- Freedman, 2020, Advisory Committee on Immunization Practices recommended immunization schedule for adults aged 19 years or older—United States, 2020, MMWR Morb Mortal Wkly Rep, 69, 133, 10.15585/mmwr.mm6905a4 · DOI
- Lee, 2018, Updated framework for development of evidence-based recommendations by the Advisory Committee on Immunization Practices, MMWR Morb Mortal Wkly Rep, 67, 1271, 10.15585/mmwr.mm6745a4 · DOI
- Goeijenbier, 2017, Benefits of flu vaccination for persons with diabetes mellitus: a review, Vaccine, 35, 5095, 10.1016/j.vaccine.2017.07.095 · DOI
- Yedlapati, 2021, Effects of influenza vaccine on mortality and cardiovascular outcomes in patients with cardiovascular disease: a systematic review and meta-analysis, J Am Heart Assoc, 10, e019636, 10.1161/JAHA.120.019636 · DOI · Paper page
- Grohskopf, 2020, Prevention and control of seasonal influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices—United States, 2020-21 influenza season, MMWR Recomm Rep, 69, 1, 10.15585/mmwr.rr6908a1 · DOI · Paper page
- Smith, 2000, Use of influenza and pneumococcal vaccines in people with diabetes, Diabetes Care, 23, 95, 10.2337/diacare.23.1.95 · DOI · Paper page
- Ahmed, 2020, Early impact of 13-valent pneumococcal conjugate vaccine use on invasive pneumococcal disease among adults with and without underlying medical conditions-United States, Clin Infect Dis, 70, 2484, 10.1093/cid/ciz739 · DOI
- Grant, 2011, Defining patient complexity from the primary care physician’s perspective: a cohort study, Ann Intern Med, 155, 797, 10.7326/0003-4819-155-12-201112200-00001 · DOI · Paper page
- Tinetti, 2012, Designing health care for the most common chronic condition—multimorbidity, JAMA, 307, 2493, 10.1001/jama.2012.5265 · DOI · Paper page
- Sudore, 2012, Symptom burden of adults with type 2 diabetes across the disease course: diabetes & aging study, J Gen Intern Med, 27, 1674, 10.1007/s11606-012-2132-3 · DOI · Paper page
- Borgnakke, 2013, Effect of periodontal disease on diabetes: systematic review of epidemiologic observational evidence, J Periodontol, 84, S135, 10.1902/jop.2013.1340013 · DOI · Paper page
- De Block, 1999, High prevalence of manifestations of gastric autoimmunity in parietal cell antibody-positive type 1 (insulin-dependent) diabetic patients. The Belgian Diabetes Registry, J Clin Endocrinol Metab, 84, 4062
- Triolo, 2011, Additional autoimmune disease found in 33% of patients at type 1 diabetes onset, Diabetes Care, 34, 1211, 10.2337/dc10-1756 · DOI · Paper page
- Kahaly, 2016, Type 1 diabetes associated autoimmunity, Autoimmun Rev, 15, 644, 10.1016/j.autrev.2016.02.017 · DOI · Paper page
- Eisenbarth, 2004, Autoimmune polyendocrine syndromes, N Engl J Med, 350, 2068, 10.1056/NEJMra030158 · DOI · Paper page
- Rubio-Tapia, 2013, ACG clinical guidelines: diagnosis and management of celiac disease, Am J Gastroenterol, 108, 656, 10.1038/ajg.2013.79 · DOI · Paper page
- Suh, 2011, Diabetes and cancer: is diabetes causally related to cancer?, Diabetes Metab J, 35, 193, 10.4093/dmj.2011.35.3.193 · DOI
- Giovannucci, 2010, Diabetes and cancer: a consensus report, CA Cancer J Clin, 60, 207, 10.3322/caac.20078 · DOI · Paper page
- Ohara, 2011, Glucose tolerance status and risk of dementia in the community: the Hisayama study, Neurology, 77, 1126, 10.1212/WNL.0b013e31822f0435 · DOI · Paper page
- Cukierman-Yaffe, 2009, Relationship between baseline glycemic control and cognitive function in individuals with type 2 diabetes and other cardiovascular risk factors: the Action to Control Cardiovascular Risk in Diabetes-Memory in Diabetes (ACCORD-MIND) trial, Diabetes Care, 32, 221, 10.2337/dc08-1153 · DOI · Paper page
- Lacy, 2020, Severe hypoglycemia and cognitive function in older adults with type 1 diabetes: the Study of Longevity in Diabetes (SOLID), Diabetes Care, 43, 541, 10.2337/dc19-0906 · DOI
- Ooi, 2011, Carbohydrates for improving the cognitive performance of independent-living older adults with normal cognition or mild cognitive impairment, Cochrane Database Syst Rev, 4, CD007220
- Lecube, 2006, Proinflammatory cytokines, insulin resistance, and insulin secretion in chronic hepatitis C patients: a case-control study, Diabetes Care, 29, 1096, 10.2337/dc05-2509 · DOI · Paper page
- Hum, 2017, Improvement in glycemic control of type 2 diabetes after successful treatment of hepatitis C virus, Diabetes Care, 40, 1173, 10.2337/dc17-0485 · DOI · Paper page
- Carnovale, 2019, The impact of a successful treatment of hepatitis C virus on glyco-metabolic control in diabetic patients: a systematic review and meta-analysis, Acta Diabetol, 56, 341, 10.1007/s00592-018-1257-1 · DOI
- Piciucchi, 2015, Exocrine pancreatic insufficiency in diabetic patients: prevalence, mechanisms, and treatment, Int J Endocrinol, 2015, 595649, 10.1155/2015/595649 · DOI
- Lee, 2016, Bidirectional relationship between diabetes and acute pancreatitis: a population-based cohort study in Taiwan, Medicine (Baltimore), 95, e2448, 10.1097/MD.0000000000002448 · DOI
- Das, 2014, Newly diagnosed diabetes mellitus after acute pancreatitis: a systematic review and meta-analysis, Gut, 63, 818, 10.1136/gutjnl-2013-305062 · DOI · Paper page
- Petrov, 2017, Diabetes of the exocrine pancreas: American Diabetes Association-compliant lexicon, Pancreatology, 17, 523, 10.1016/j.pan.2017.06.007 · DOI
- Tkac, 2017, Combined analysis of three large interventional trials with gliptins indicates increased incidence of acute pancreatitis in patients with type 2 diabetes, Diabetes Care, 40, 284, 10.2337/dc15-1707 · DOI
- Bellin, 2015, Total pancreatectomy with islet autotransplantation: summary of an NIDDK workshop, Ann Surg, 261, 21, 10.1097/SLA.0000000000001059 · DOI
- Sutherland, 2012, Total pancreatectomy and islet autotransplantation for chronic pancreatitis, J Am Coll Surg, 214, 409, 10.1016/j.jamcollsurg.2011.12.040 · DOI · Paper page
- Webb, 2008, Islet auto transplantation following total pancreatectomy: a long-term assessment of graft function, Pancreas, 37, 282, 10.1097/mpa.0b013e31816fd7b6 · DOI
- Wu, 2015, Systematic review and meta-analysis of islet autotransplantation after total pancreatectomy in chronic pancreatitis patients, Endocr J, 62, 227, 10.1507/endocrj.EJ14-0510 · DOI
- Janghorbani, 2007, Systematic review of type 1 and type 2 diabetes mellitus and risk of fracture, Am J Epidemiol, 166, 495, 10.1093/aje/kwm106 · DOI · Paper page
- Vestergaard, 2007, Discrepancies in bone mineral density and fracture risk in patients with type 1 and type 2 diabetes—a meta-analysis, Osteoporos Int, 18, 427, 10.1007/s00198-006-0253-4 · DOI · Paper page
- Schwartz, 2011, Study of Osteoporotic Fractures (SOF) Research Group; Osteoporotic Fractures in Men (MrOS) Research Group; Health, Aging, and Body Composition (Health ABC) Research Group. Association of BMD and FRAX score with risk of fracture in older adults with type 2 diabetes, JAMA, 305, 2184, 10.1001/jama.2011.715 · DOI · Paper page
- Taylor, 2015, Possible adverse effects of SGLT2 inhibitors on bone, Lancet Diabetes Endocrinol, 3, 8, 10.1016/S2213-8587(14)70227-X · DOI · Paper page
- Baiduc, 2019, Epidemiology of diabetes and hearing loss, Semin Hear, 40, 281, 10.1055/s-0039-1697643 · DOI
- Helzner, 2016, Type 2 diabetes and hearing impairment, Curr Diab Rep, 16, 3, 10.1007/s11892-015-0696-0 · DOI
- Bainbridge, 2008, Diabetes and hearing impairment in the United States: audiometric evidence from the National Health and Nutrition Examination Survey, 1999 to 2004, Ann Intern Med, 149, 1, 10.7326/0003-4819-149-1-200807010-00231 · DOI · Paper page
- Schade, 2018, Hearing impairment and type 1 diabetes in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) cohort, Diabetes Care, 41, 2495, 10.2337/dc18-0625 · DOI
- Rasmussen, 2018, Prevalence of taste and smell impairment in adults with diabetes: a cross-sectional analysis of data from the National Health and Nutrition Examination Survey (NHANES), Prim Care Diabetes, 12, 453, 10.1016/j.pcd.2018.05.006 · DOI
- Li, 2010, Prevalence of self-reported clinically diagnosed sleep apnea according to obesity status in men and women: National Health and Nutrition Examination Survey, 2005–2006, Prev, 51, 18
- West, 2006, Prevalence of obstructive sleep apnoea in men with type 2 diabetes, Thorax, 61, 945, 10.1136/thx.2005.057745 · DOI · Paper page
- Bibbins-Domingo, 2017, Screening for obstructive sleep apnea in adults: US Preventive Services Task Force recommendation statement, JAMA, 317, 407, 10.1001/jama.2016.20325 · DOI · Paper page
- Shaw, 2008, Sleep-disordered breathing and type 2 diabetes: a report from the International Diabetes Federation Taskforce on Epidemiology and Prevention, Diabetes Res Clin Pract, 81, 2, 10.1016/j.diabres.2008.04.025 · DOI · Paper page
- Khader, 2006, Periodontal status of diabetics compared with nondiabetics: a meta-analysis, J Diabetes Complications, 20, 59, 10.1016/j.jdiacomp.2005.05.006 · DOI · Paper page
- Casanova, 2014, Diabetes and periodontal disease: a two-way relationship, Br Dent J, 217, 433, 10.1038/sj.bdj.2014.907 · DOI · Paper page
- Simpson, 2015, Treatment of periodontal disease for glycaemic control in people with diabetes mellitus, Cochrane Database Syst Rev, CD004714
- Lomonaco, 2021, Advanced liver fibrosis is common in patients with type 2 diabetes followed in the outpatient setting: the need for systematic screening, Diabetes Care, 44, 399, 10.2337/dc20-1997 · DOI · Paper page
- Ciardullo, 2021, High prevalence of advanced liver fibrosis assessed by transient elastography among U.S. adults with type 2 diabetes, Diabetes Care, 44, 519, 10.2337/dc20-1778 · DOI · Paper page
- Barb, 2021, Type 2 diabetes mellitus increases the risk of hepatic fibrosis in individuals with obesity and nonalcoholic fatty liver disease, Obesity (Silver Spring), 29, 1950, 10.1002/oby.23263 · DOI
- Stefan, 2022, A global view of the interplay between non-alcoholic fatty liver disease and diabetes, Lancet Diabetes Endocrinol, 10, 284, 10.1016/S2213-8587(22)00003-1 · DOI · Paper page
- Paik, 2020, Changes in the global burden of chronic liver diseases from 2012 to 2017: the growing impact of NAFLD, Hepatology, 72, 1605, 10.1002/hep.31173 · DOI · Paper page
- Simon, 2021, Mortality in biopsy-confirmed nonalcoholic fatty liver disease: results from a nationwide cohort, Gut, 70, 1375, 10.1136/gutjnl-2020-322786 · DOI · Paper page
- Burra, 2020, NAFLD and liver transplantation: disease burden, current management and future challenges, JHEP Rep, 2, 100192, 10.1016/j.jhepr.2020.100192 · DOI · Paper page
- Younossi, 2022, A global survey of physicians knowledge about nonalcoholic fatty liver disease, Clin Gastroenterol Hepatol, 20, e1456, 10.1016/j.cgh.2021.06.048 · DOI · Paper page
- Kanwal, 2021, Preparing for the NASH epidemic: a call to action, Diabetes Care, 44, 2162, 10.2337/dci21-0020 · DOI
- Kanwal, 2021, Clinical care pathway for the risk stratification and management of patients with nonalcoholic fatty liver disease, Gastroenterology, 161, 1657, 10.1053/j.gastro.2021.07.049 · DOI · Paper page
- Gellert-Kristensen, 2020, Combined effect of PNPLA3, TM6SF2, and HSD17B13 variants on risk of cirrhosis and hepatocellular carcinoma in the general population, Hepatology, 72, 845, 10.1002/hep.31238 · DOI · Paper page
- Stender, 2017, Adiposity amplifies the genetic risk of fatty liver disease conferred by multiple loci, Nat Genet, 49, 842, 10.1038/ng.3855 · DOI · Paper page
- Angulo, 2015, Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease, Gastroenterology, 149, 389, 10.1053/j.gastro.2015.04.043 · DOI · Paper page
- Mantovani, 2018, Nonalcoholic fatty liver disease and risk of incident type 2 diabetes: a meta-analysis, Diabetes Care, 41, 372, 10.2337/dc17-1902 · DOI · Paper page
- Duell, 2022, Nonalcoholic fatty liver disease and cardiovascular risk: a scientific statement from the American Heart Association, Arterioscler Thromb Vasc Biol, 42, e168, 10.1161/ATV.0000000000000153 · DOI · Paper page
- Ciardullo, 2022, Liver stiffness, albuminuria and chronic kidney disease in patients with NAFLD: a systematic review and meta-analysis, Biomolecules, 12, 105, 10.3390/biom12010105 · DOI
- Musso, 2014, Association of non-alcoholic fatty liver disease with chronic kidney disease: a systematic review and meta-analysis, PLoS Med, 11, e1001680, 10.1371/journal.pmed.1001680 · DOI · Paper page
- Song, 2021, Association of non-alcoholic fatty liver disease with diabetic retinopathy in type 2 diabetic patients: a meta-analysis of observational studies, J Diabetes Investig, 12, 1471, 10.1111/jdi.13489 · DOI
- de Vries, 2020, Prevalence of nonalcoholic fatty liver disease (NAFLD) in patients with type 1 diabetes mellitus: a systematic review and meta-analysis, J Clin Endocrinol Metab, 105, dgaa575, 10.1210/clinem/dgaa575 · DOI
- Cusi, 2017, Non-alcoholic fatty liver disease (NAFLD) prevalence and its metabolic associations in patients with type 1 diabetes and type 2 diabetes, Diabetes Obes Metab, 19, 1630, 10.1111/dom.12973 · DOI · Paper page
- Arab, 2020, Latin American Association for the Study of the Liver (ALEH) practice guidance for the diagnosis and treatment of non-alcoholic fatty liver disease, Ann Hepatol, 19, 674, 10.1016/j.aohep.2020.09.006 · DOI
- Eslam, 2020, The Asian Pacific Association for the Study of the Liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease, Hepatol Int, 14, 889, 10.1007/s12072-020-10094-2 · DOI · Paper page
- Maximos M , BrilF, Portillo Sanchez, The role of liver fat and insulin resistance as determinants of plasma aminotransferase elevation in nonalcoholic fatty liver disease. Hepatology2014;61:153–160 · DOI · Paper page
- Unalp-Arida, 2017, Liver fibrosis scores predict liver disease mortality in the United States population, Hepatology, 66, 84, 10.1002/hep.29113 · DOI · Paper page
- Lee, 2021, Prognostic accuracy of FIB-4, NAFLD fibrosis score and APRI for NAFLD-related events: a systematic review, Liver Int, 41, 261, 10.1111/liv.14669 · DOI · Paper page
- Qadri, 2022, Obesity modifies the performance of fibrosis biomarkers in nonalcoholic fatty liver disease, J Clin Endocrinol Metab, 107, e2008, 10.1210/clinem/dgab933 · DOI
- Bril, 2020, Performance of plasma biomarkers and diagnostic panels for nonalcoholic steatohepatitis and advanced fibrosis in patients with type 2 diabetes, Diabetes Care, 43, 290, 10.2337/dc19-1071 · DOI · Paper page
- Anstee, 2019, Noninvasive tests accurately identify advanced fibrosis due to NASH: baseline data from the STELLAR trials, Hepatology, 70, 1521, 10.1002/hep.30842 · DOI · Paper page
- Singh, 2020, Accuracy of noninvasive fibrosis scores to detect advanced fibrosis in patients with type-2 diabetes with biopsy-proven nonalcoholic fatty liver disease, J Clin Gastroenterol, 54, 891, 10.1097/MCG.0000000000001339 · DOI
- Ishiba, 2018, The novel cutoff points for the FIB4 index categorized by age increase the diagnostic accuracy in NAFLD: a multi-center study, J Gastroenterol, 53, 1216, 10.1007/s00535-018-1474-y · DOI
- Castera, 2019, Noninvasive assessment of liver disease in patients with nonalcoholic fatty liver disease, Gastroenterology, 156, 1264, 10.1053/j.gastro.2018.12.036 · DOI · Paper page
- Eddowes, 2019, Accuracy of FibroScan controlled attenuation parameter and liver stiffness measurement in assessing steatosis and fibrosis in patients with nonalcoholic fatty liver disease, Gastroenterology, 156, 1717, 10.1053/j.gastro.2019.01.042 · DOI · Paper page
- Mózes, 2022, Diagnostic accuracy of non-invasive tests for advanced fibrosis in patients with NAFLD: an individual patient data meta-analysis, Gut, 71, 1006, 10.1136/gutjnl-2021-324243 · DOI · Paper page
- Elhence, 2022, Compensated advanced chronic liver disease in nonalcoholic fatty liver disease: two-step strategy is better than Baveno criteria, Dig Dis Sci
- Chan, 2019, Optimizing use of nonalcoholic fatty liver disease fibrosis score, fibrosis-4 score, and liver stiffness measurement to identify patients with advanced fibrosis, Clin Gastroenterol Hepatol, 17, 2570, 10.1016/j.cgh.2019.03.006 · DOI
- Petta, 2019, Impact of obesity and alanine aminotransferase levels on the diagnostic accuracy for advanced liver fibrosis of noninvasive tools in patients with nonalcoholic fatty liver disease, Am J Gastroenterol, 114, 916, 10.14309/ajg.0000000000000153 · DOI
- Lazarus, 2021, Defining comprehensive models of care for NAFLD, Nat Rev Gastroenterol Hepatol, 18, 717, 10.1038/s41575-021-00477-7 · DOI
- Wong, 2022, Management of NAFLD in primary care settings, Liver Int, 42, 2377, 10.1111/liv.15404 · DOI
- Long, 2022, AGA clinical practice update: diagnosis and management of nonalcoholic fatty liver disease in lean individuals: expert review, Gastroenterology, 163, 764, 10.1053/j.gastro.2022.06.023 · DOI · Paper page
- Cusi, 2017, Nonalcoholic steatohepatitis in nonobese patients: not so different after all, Hepatology, 65, 4, 10.1002/hep.28839 · DOI
- Cusi, 2012, Role of obesity and lipotoxicity in the development of nonalcoholic steatohepatitis: pathophysiology and clinical implications, Gastroenterology, 142, 711, 10.1053/j.gastro.2012.02.003 · DOI · Paper page
- Akbulut, 2022, The effect of a Mediterranean diet vs. a low-fat diet on non-alcoholic fatty liver disease in children: a randomized trial, Int J Food Sci Nutr, 73, 357, 10.1080/09637486.2021.1979478 · DOI
- Promrat, 2010, Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis, Hepatology, 51, 121, 10.1002/hep.23276 · DOI · Paper page
- Vilar-Gomez, 2015, Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis, Gastroenterology, 149, 367, 10.1053/j.gastro.2015.04.005 · DOI · Paper page
- Gepner, 2019, The beneficial effects of Mediterranean diet over low-fat diet may be mediated by decreasing hepatic fat content, J Hepatol, 71, 379, 10.1016/j.jhep.2019.04.013 · DOI · Paper page
- Younossi, 2021, AGA clinical practice update on lifestyle modification using diet and exercise to achieve weight loss in the management of nonalcoholic fatty liver disease: expert review, Gastroenterology, 160, 912, 10.1053/j.gastro.2020.11.051 · DOI · Paper page
- Plauth, 2019, ESPEN guideline on clinical nutrition in liver disease, Clin Nutr, 38, 485, 10.1016/j.clnu.2018.12.022 · DOI · Paper page
- Orci, 2016, Exercise-based interventions for nonalcoholic fatty liver disease: a meta-analysis and meta-regression, Clin Gastroenterol Hepatol, 14, 1398, 10.1016/j.cgh.2016.04.036 · DOI · Paper page
- Younossi, 2018, The conundrum of cryptogenic cirrhosis: Adverse outcomes without treatment options, J Hepatol, 69, 1365, 10.1016/j.jhep.2018.08.013 · DOI
- Patel Chavez, 2022, The emerging role of glucagon-like peptide-1 receptor agonists for the management of NAFLD, J Clin Endocrinol Metab, 107, 29, 10.1210/clinem/dgab578 · DOI · Paper page
- Budd, 2020, Role of agents for the treatment of diabetes in the management of nonalcoholic fatty liver disease, Curr Diab Rep, 20, 59, 10.1007/s11892-020-01349-1 · DOI
- Huang, 2021, First-in-Asian double-blind randomized trial to assess the efficacy and safety of insulin sensitizer in nonalcoholic steatohepatitis patients, Hepatol Int, 15, 1136, 10.1007/s12072-021-10242-2 · doi:10.1007/s12072-021-10242-2
- Noureddin, 2020, Screening for nonalcoholic fatty liver disease in persons with type 2 diabetes in the United States is cost-effective: a comprehensive cost-utility analysis, Gastroenterology, 159, 1985, 10.1053/j.gastro.2020.07.050 · DOI · Paper page
- Mahady, 2012, Pioglitazone and vitamin E for nonalcoholic steatohepatitis: a cost utility analysis, Hepatology, 56, 2172, 10.1002/hep.25887 · DOI
- Armstrong, 2016, Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study, Lancet, 387, 679, 10.1016/S0140-6736(15)00803-X · DOI · Paper page
- Gastaldelli, 2022, Effect of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes (SURPASS-3 MRI): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial, Lancet Diabetes Endocrinol, 10, 393, 10.1016/S2213-8587(22)00070-5 · DOI · Paper page
- Castera, 2023, Diabetes and cirrhosis: current concepts on diagnosis and management, Hepatology, 77, 2128, 10.1097/HEP.0000000000000263 · DOI
- Loomba, 2023, Semaglutide 2·4 mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trial, Lancet Gastroenterol Hepatol, 8, 511, 10.1016/S2468-1253(23)00068-7 · DOI · Paper page
- Ramai, 2021, Systematic review with meta-analysis: bariatric surgery reduces the incidence of hepatocellular carcinoma, Aliment Pharmacol Ther, 53, 977, 10.1111/apt.16335 · DOI
- Kim, 2017, Statin use and risk of cirrhosis and related complications in patients with chronic liver diseases: a systematic review and meta-analysis, Clin Gastroenterol Hepatol, 15, 1521, 10.1016/j.cgh.2017.04.039 · DOI · Paper page
- Kaplan, 2019, Effects of hypercholesterolemia and statin exposure on survival in a large national cohort of patients with cirrhosis, Gastroenterology, 156, 1693, 10.1053/j.gastro.2019.01.026 · DOI · Paper page
- Roberts, 2020, COVID-19: a complex multisystem disorder, Br J Anaesth, 125, 238, 10.1016/j.bja.2020.06.013 · DOI
- Chudasama, 2021, Patterns of multimorbidity and risk of severe SARS-CoV-2 infection: an observational study in the U.K, BMC Infect Dis, 21, 908, 10.1186/s12879-021-06600-y · DOI
- Holman, 2020, Risk factors for COVID-19-related mortality in people with type 1 and type 2 diabetes in England: a population-based cohort study, Lancet Diabetes Endocrinol, 8, 823, 10.1016/S2213-8587(20)30271-0 · DOI · Paper page
- Martin, 2020, Socio-demographic heterogeneity in the prevalence of COVID-19 during lockdown is associated with ethnicity and household size: results from an observational cohort study, EClinicalMedicine, 25, 100466, 10.1016/j.eclinm.2020.100466 · DOI
- Singh, 2020, Prevalence of co-morbidities and their association with mortality in patients with COVID-19: a systematic review and meta-analysis, Diabetes Obes Metab, 22, 1915, 10.1111/dom.14124 · DOI · Paper page
- Hartmann-Boyce, 2020, Diabetes and COVID-19: risks, management, and learnings from other national disasters, Diabetes Care, 43, 1695, 10.2337/dc20-1192 · DOI · Paper page
- Hartmann-Boyce, 2021, Risks of and from SARS-CoV-2 infection and COVID-19 in people with diabetes: a systematic review of reviews, Diabetes Care, 44, 2790, 10.2337/dc21-0930 · DOI
- Barron, 2020, Associations of type 1 and type 2 diabetes with COVID-19-related mortality in England: a whole-population study, Lancet Diabetes Endocrinol, 8, 813, 10.1016/S2213-8587(20)30272-2 · DOI · Paper page
- Khunti, 2023, The impact of the COVID-19 pandemic on ethnic minority groups with diabetes, Diabetes Care, 46, 228, 10.2337/dc21-2495 · DOI
- Chen, 2022, Global prevalence of post COVID-19 condition or long COVID: a meta-analysis and systematic review, J Infect Dis, 226, 1593, 10.1093/infdis/jiac136 · DOI · Paper page
- Khunti, 2021, COVID-19, hyperglycemia, and new-onset diabetes, Diabetes Care, 44, 2645, 10.2337/dc21-1318 · DOI · Paper page
- Qeadan, 2022, The associations between COVID-19 diagnosis, type 1 diabetes, and the risk of diabetic ketoacidosis: a nationwide cohort from the US using the Cerner Real-World Data, PLoS One, 17, e0266809, 10.1371/journal.pone.0266809 · DOI
- Shulman, 2022, Examination of trends in diabetes incidence among children during the COVID-19 pandemic in Ontario, Canada, from March 2020 to September 2021, JAMA Netw Open, 5, e2223394, 10.1001/jamanetworkopen.2022.23394 · DOI
- Kamrath, 2020, Ketoacidosis in children and adolescents with newly diagnosed type 1 diabetes during the COVID-19 pandemic in Germany, JAMA, 324, 801, 10.1001/jama.2020.13445 · DOI · Paper page
- Misra, 2021, Temporal trends in emergency admissions for diabetic ketoacidosis in people with diabetes in England before and during the COVID-19 pandemic: a population-based study, Lancet Diabetes Endocrinol, 9, 671, 10.1016/S2213-8587(21)00208-4 · DOI
- Violant-Holz, 2020, Psychological health and physical activity levels during the COVID-19 pandemic: a systematic review, Int J Environ Res Public Health, 17, E9419, 10.3390/ijerph17249419 · DOI · Paper page
- Alessi, 2022, One in ten patients with diabetes have suicidal thoughts after 1 year of the COVID-19 pandemic: we need to talk about diabetes and mental health not only during Suicide Prevention Awareness Month, Acta Diabetol, 59, 143, 10.1007/s00592-021-01807-6 · doi:10.1007/s00592-021-01807-6
- Chao, 2022, Changes in the prevalence of symptoms of depression, loneliness, and insomnia in U.S. older adults with type 2 diabetes during the COVID-19 pandemic: the Look AHEAD Study, Diabetes Care, 45, 74, 10.2337/dc21-1179 · DOI
- Stockwell, 2021, Changes in physical activity and sedentary behaviours from before to during the COVID-19 pandemic lockdown: a systematic review, BMJ Open Sport Exerc Med, 7, e000960, 10.1136/bmjsem-2020-000960 · DOI · Paper page
- O’Donnell MB , HilliardME, CaoVT, “It just kind of feels like a different world now:” stress and resilience for adolescents with type 1 diabetes in the era of COVID-19. Front Clin Diabetes Healthcare. Accessed 7 October 2022. Available from https://www.frontiersin.org/articles/10.3389/fcdhc.2022.835739 · DOI
- Wang, 2021, Predictors of mood, diabetes-specific and COVID-19-specific experiences among parents of early school-age children with type 1 diabetes during initial months of the COVID-19 pandemic, Pediatr Diabetes, 22, 1071, 10.1111/pedi.13255 · DOI
- Ferguson, Impacts of the COVID-19 pandemic on pediatric type 1 diabetes management: a qualitative study, Sci Diabetes Self Manag Care.
- Mohseni, 2021, Challenges of routine diabetes care during COVID-19 era: a systematic search and narrative review, Prim Care Diabetes, 15, 918, 10.1016/j.pcd.2021.07.017 · DOI
- Ratzki-Leewing, 2021, COVID-19 hinterland: surveilling the self-reported impacts of the pandemic on diabetes management in the USA (cross-sectional results of the iNPHORM study), BMJ Open, 11, e049782, 10.1136/bmjopen-2021-049782 · DOI
- Seidu, 2022, The impact of the COVID pandemic on primary care diabetes services in the UK: a cross-sectional national survey of views of health professionals delivering diabetes care, Prim Care Diabetes, 16, 257, 10.1016/j.pcd.2021.12.015 · DOI
- Carr, 2022, Impact of COVID-19 restrictions on diabetes health checks and prescribing for people with type 2 diabetes: a UK-wide cohort study involving 618 161 people in primary care, BMJ Qual Saf, 31, 503, 10.1136/bmjqs-2021-013613 · DOI · Paper page
- Vamos, 2022, Indirect effects of the COVID-19 pandemic on people with type 2 diabetes: time to urgently move into a recovery phase, BMJ Qual Saf, 31, 483, 10.1136/bmjqs-2021-014079 · DOI
- Valabhji, 2022, Associations between reductions in routine care delivery and non-COVID-19-related mortality in people with diabetes in England during the COVID-19 pandemic: a population-based parallel cohort study, Lancet Diabetes Endocrinol, 10, 561, 10.1016/S2213-8587(22)00131-0 · doi:10.1016/s2213-8587(22)00131-0
- DiabetesontheNet . How to undertake a remote diabetes review. Accessed 29 August 2022. Available from https://diabetesonthenet.com/diabetes-primary-care/how-undertake-remote-diabetes-review/
- Nagi, 2021, ABCD position statement on risk stratification of adult patients with diabetes during COVID-19 pandemic, British Journal of Diabetes., 21, 123, 10.15277/bjd.2021.282 · DOI
- Alessi, 2021, Telehealth strategy to mitigate the negative psychological impact of the COVID-19 pandemic on type 2 diabetes: a randomized controlled trial, Acta Diabetol, 58, 899, 10.1007/s00592-021-01690-1 · DOI
- Kilvert, 2020, Virtual consultations: are we missing anything?, Pract Diabetes, 37, 143, 10.1002/pdi.2288 · DOI
- Khunti, 2021, Prescription of glucose-lowering therapies and risk of COVID-19 mortality in people with type 2 diabetes: a nationwide observational study in England, Lancet Diabetes Endocrinol, 9, 293, 10.1016/S2213-8587(21)00050-4 · DOI · Paper page
- Kosiborod, 2021, Dapagliflozin in patients with cardiometabolic risk factors hospitalised with COVID-19 (DARE-19): a randomised, double-blind, placebo-controlled, phase 3 trial, Lancet Diabetes Endocrinol, 9, 586, 10.1016/S2213-8587(21)00180-7 · DOI · Paper page
- Czeisler, 2021, Health care access and use among adults with diabetes during the COVID-19 pandemic - United States, February-March 2021, MMWR Morb Mortal Wkly Rep, 70, 1597, 10.15585/mmwr.mm7046a2 · DOI
- Lipska, 2014, National trends in US hospital admissions for hyperglycemia and hypoglycemia among Medicare beneficiaries, 1999 to 2011, JAMA Intern Med, 174, 1116, 10.1001/jamainternmed.2014.1824 · DOI · Paper page
- Shorr, 1997, Incidence and risk factors for serious hypoglycemia in older persons using insulin or sulfonylureas, Arch Intern Med, 157, 1681, 10.1001/archinte.1997.00440360095010 · DOI · Paper page
- Abdelhafiz, 2015, Hypoglycemia in older people–a less well recognized risk factor for frailty, Aging Dis, 6, 156, 10.14336/AD.2014.0330 · DOI · Paper page
- Yun, 2013, Presence of macroalbuminuria predicts severe hypoglycemia in patients with type 2 diabetes: a 10-year follow-up study, Diabetes Care, 36, 1283, 10.2337/dc12-1408 · DOI
- Chelliah, 2004, Hypoglycaemia in elderly patients with diabetes mellitus: causes and strategies for prevention, Drugs Aging, 21, 511, 10.2165/00002512-200421080-00003 · DOI · Paper page
- Centers for Disease Control and Prevention (CDC), 2011, Use of hepatitis B vaccination for adults with diabetes mellitus: recommendations of the Advisory Committee on Immunization Practices (ACIP), MMWR Morb Mortal Wkly Rep, 60, 1709
- Demicheli, 2018, Vaccines for preventing influenza in the elderly, Cochrane Database Syst Rev, 2, CD004876
- Centers for Disease Control and Prevention (CDC), 2010, Updated recommendations for prevention of invasive pneumococcal disease among adults using the 23-valent pneumococcal polysaccharide vaccine (PPSV23), MMWR Morb Mortal Wkly Rep, 59, 1102
- Falkenhorst, 2017, Effectiveness of the 23-valent pneumococcal polysaccharide vaccine (PPV23) against pneumococcal disease in the elderly: systematic review and meta-analysis, PLoS One, 12, e0169368, 10.1371/journal.pone.0169368 · DOI · Paper page
- Dooling, 2018, Recommendations of the Advisory Committee on Immunization Practices for use of herpes zoster vaccines, MMWR Morb Mortal Wkly Rep, 67, 103, 10.15585/mmwr.mm6703a5 · DOI · Paper page
Cited by
Changing epidemiology, global trends and implications for outcomes of NAFLD
Wong, V. W.-S., Ekstedt, M., Wong, G. L.-H., & Hagström, H. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2023.04.036 · Cited by 765
Younossi, Z. M., Golabi, P., Price, J. K., Owrangi, S., Gundu-Rao, N., Satchi, R., & Paik, J. M. (2024) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2024.03.006 · Cited by 416
Self-citationSelective Agonists of Thyroid Hormone Receptor Beta for the Treatment of NASH
Cusi, K. (2024) · New England Journal of Medicine · doi:10.1056/nejme2314365 · Cited by 78
Self-citationImplementation of a liver health check in people with type 2 diabetes
Abeysekera, K. W. M., Valenti, L., Younossi, Z., Dillon, J. F., Allen, A. M., Noureddin, M., Rinella, M. E., Tacke, F., Francque, S., Ginès, P., et al. (2024) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(23)00270-4 · Cited by 63
Self-citationPosttransplant diabetes mellitus: recent developments in pharmacological management of hyperglycemia
Munoz Pena, J. M., & Cusi, K. (2023) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgad395 · Cited by 24
Self-citation
Metadata
- Authors
- ElSayed, N. A., Aleppo, G., Aroda, V. R., Bannuru, R. R., Brown, F. M., Bruemmer, D., Collins, B. S., Cusi, K., Hilliard, M. E., Isaacs, D., Johnson, E. L., Kahan, S., Khunti, K., Leon, J., Lyons, S. K., Perry, M. L., Prahalad, P., Pratley, R. E., Seley, J. J., Stanton, R. C., Younossi, Z., Gabbay, R. A., & American Diabetes Association
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2022-12-12
- Volume
- 46
- Issue
- Supplement_1
- Pages
- s49-s67.2
- ISSN
- 0149-5992 (ISSN-L)
- OpenAlex
- W4311264007
- Cited by
- 222
- References
- 79
- FWCI
- 30.12
- Type
- journal article
- Language
- en
- Update notices
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: 4. Comprehensive Medical Evaluation and Assessment of Comorbidities:Standards of Care in Diabetes—2023. https://app.cochat.ai/papers/10.2337/dc23-s004
- The paper
- ElSayed, N. A., Aleppo, G., Aroda, V. R., Bannuru, R. R., Brown, F. M., Bruemmer, D., Collins, B. S., Cusi, K., Hilliard, M. E., Isaacs, D., Johnson, E. L., Kahan, S., Khunti, K., Leon, J., Lyons, S. K., Perry, M. L., Prahalad, P., Pratley, R. E., Seley, J. J., . . . American Diabetes Association. (2023). 4. Comprehensive Medical Evaluation and Assessment of Comorbidities:Standards of Care in Diabetes—2023. Diabetes Care. https://doi.org/10.2337/dc23-s004
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.